Sp1 and Sp3 effects on the transcription of the human ␣1(II) procollagen gene (COL2A1) were investigated in both differentiated and de-differentiated rabbit articular chondrocytes. Transient transfection with constructs of deleted COL2A1 promoter sequences driving the luciferase reporter gene revealed that the region spanning ؊266 to ؉121 base pairs showed Sp1-enhancing effects, whatever the differentiation state. In contrast, Sp3 did not influence COL2A1 gene transcription. Concomitant overexpression of the two Sp proteins demonstrated that Sp3 blocked the Sp1 induction of COL2A1 promoter activity. Moreover, inhibition of Sp1/ Sp3 binding to their target DNA sequence decreased both COL2A1 gene transcription and Sp1-enhancing effects. DNase I footprinting and gel retardation assays revealed that Sp1 and Sp3 bind specifically to cis-sequences of the COL2A1 gene promoter whereby they exert their transcriptional effects. Sp1 and Sp3 levels were found to be reduced in de-differentiated chondrocytes, as revealed by DNA-binding and immunochemical study. Sp1 specifically activated collagen neosynthesis whatever the differentiation state of chondrocytes, suggesting that this factor exerts a major role in the expression of collagen type II. However, our data indicate that type II collagen-specific expression in chondrocytes depend on both the Sp1/Sp3 ratio and cooperation of Sp1 with other transcription factors, the amounts of which are also modulated by phenotype alteration.Differentiation of mesenchymal cells into chondrocytes results in the synthesis and secretion of a series of proteins characteristic of the cartilage matrix, including type II, IX, XI, and X collagens, the proteoglycan aggrecan, link protein, and cartilage matrix protein (1, 2). Type II collagen is considered as a critical phenotypic marker gene for analysis of molecular events involved in chondrogenesis process as well as in chondrocyte phenotype maintenance. Alteration of type II collagen expression in cartilage may be due to a variety of genetic, inflammatory, or degenerative circumstances and may lead to a variety of chondrodysplasias and joint diseases such as osteoarthritis (3-8). In osteoarthritis, chondrocytes undergo dedifferentiation and synthesize types I and III collagens at the expense of type II (9 -11). Similarly, when chondrocytes are subcultured in vitro as monolayers, they progressively reduce their synthesis of type II collagen (12-14), mimicking the behavior of osteoarthritic chondrocytes. However, they can recover the chondrocytic phenotype by transfer to three-dimensional culture systems (14 -16). Therefore, in vitro analysis of the molecular mechanisms that regulate COL2A1 gene expression can be an approach to understand the process of phenotype alteration in chondrocytes, and its impact on joint diseases.A 48-bp 1 minimal DNA element has been identified as an enhancer that directs chondrocyte-specific expression of the COL2A1 gene in transgenic mice (17)(18)(19). Such an element was also found in the rat COL2A1 gene (20, 21). ...

Although transforming growth factor ␤1 (TGF-␤1) is generally considered as a stimulator of type I collagen production in smooth organs, we found that it can inhibit type II collagen biosynthesis in primary rabbit articular chondrocytes (RAC) at transcriptional levels. Constructs of promoter and first intron sequences associated with the luciferase reporter gene were used to delineate the gene sequences involved in TGF-␤1 control of human COL2A1 gene transcription. Cotransfection of these DNA fragments with a T␤RII/I cDNA hybrid receptor, capable of inducing a TGF-␤1 dominant negative effect, showed that TGF-␤1 inhibits specifically COL2A1 gene transcription in RAC by a 63-bp proximal promoter. Footprint and gel retardation analyses revealed that the TGF-␤1-induced inhibition effect exerted through the 63-bp promoter sequence implies a multimeric complex that binds to the ؊41/؊33 sequence and involves Sp1 and Sp3 transcription factors. Transfection of decoy Sp-binding oligonucleotides corroborated the implication of the proximal promoter in the TGF-␤1-induced inhibition of COL2A1 gene transcription. In addition, TGF-␤1 was found to increase the expression of Sp3 without significant changes to its binding level, but repressed both the biosynthesis and binding activity of Sp1. In functional assays, Sp3 inhibited the 63-bp promoter activity and prevented Sp1 induction of transcription. These findings suggest that TGF-␤1 inhibition of COL2A1 gene transcription in RAC is mediated by an increase of the Sp3/Sp1 ratio and by the repression of Sp1 transactivating effects on that gene.

The results suggest that diacerein effects on matrix synthesis and turn-over previously reported in cultured articular chondrocytes might be explained in part by the ability of the drug to enhance TGF-beta1 and TGF-beta2 expression in these cells. This mechanism of action may account for the potential disease-modifying properties of diacerein and might give clues as to how future anti-osteoarthritic drugs should be designed.

No abstract